Suchergebnisse - "Scribano, Maria Lia"

PubPharm (6)

1

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease : the IG-IBD LIVE study

enthalten in: Alimentary pharmacology & therapeutics | 2022

von Pugliese, D. | Privitera, G. | Crispino, F. | +58

CommentIn: Aliment Pharmacol Ther. 2022 Aug;56(4):731-732. - PMID 35879894

2

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease : an international, randomised, double-blind, phase 3 non-inferiority study

enthalten in: Lancet (London, England) | 2019

von Ye, B. | Pesegova, M. | Alexeeva, O. | +17

CommentIn: Lancet. 2019 Apr 27;393(10182):1671-1672. - PMID 30929894

3

Vedolizumab for inflammatory bowel disease : From randomized controlled trials to real-life evidence

enthalten in: World journal of gastroenterology | 2018

von Scribano, M.

4

Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome

enthalten in: Journal of gastrointestinal and liver diseases : JGLD | 2016

von Portincasa, P. | Bonfrate, L. | Scribano, M. | +10

5

Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease

enthalten in: Gastroenterology | 2012

von Prantera, C. | Lochs, H. | Grimaldi, M. | +57

CommentIn: Nat Rev Gastroenterol Hepatol. 2012 Feb;9(2):62. - PMID 22249735

6

Adverse events of IBD therapies

enthalten in: Inflammatory bowel diseases | 2008

von Scribano, M.

ErratumIn: Inflamm Bowel Dis. 2009 Sep;15(9):1438-47

1
[1]